Problem · updated 2026-11-20
Heart disease
The leading cause of death worldwide: 9,469,357 deaths from ischaemic heart disease in 2023.
Every number below has a source · Download this data
254.3M
people affected
Liang et al., Frontiers in Public Health, 2025, analysis of GBD 2021: 254,276,268 prevalent ischaemic heart disease cases in 2021, up from 112,169,488 in 1990.694,708
US heart disease deaths, 2025, provisional
NCHS Vital Statistics Rapid Release No. 44 (July 2026): heart disease was the leading cause of death in 2025, with 694,708 deaths. Provisional data as of 10 May 2026. This is all heart disease, not the global ischaemic heart disease count. Checked 2026-11-20.Heart disease
people living with ischaemic heart disease
Data table
| Year | Value |
|---|---|
| 1990 | 112,169,488 |
| 2021 | 254,276,268 |
Neglectedness
3
score out of 10. Higher means more neglected.
WHO Global Health Estimates 2023 deaths workbook; SELECT, NEJMAs of 2026-11-20
Tractability
7
score out of 10. Higher means effort buys more progress.
SELECT and VESALIUS-CV, New England Journal of MedicineAs of 2026-11-20
What you can do
Open dataBuild
Startups, labs, open work
Startup
CleerlyBuilds FDA-cleared software that reads coronary plaque and stenosis from CT. An updated Cleerly LABS was cleared on 30 October 2026.
Checked 2026-11-20
Startup
CuoripsJapan conditionally approved its iPSC-derived cardiomyocyte sheet on 6 March 2026 for severe ischemic heart failure.
Checked 2026-11-20
Fund
Grants, prizes, funders
None yet.
Buy
Products to use or back
Product
Cleerly LABSCoronary CT analysis software. The FDA cleared an updated version, including the PLAQUE algorithm, on 30 October 2026.
Checked 2026-11-20
Learn
Explainers and papers
Paper
VERVE-102Phase 1 study of VERVE-102, a base-editing therapy designed to inactivate PCSK9 in the liver. NEJM, 2026.
Checked 2026-11-20
Paper
CTX310Phase 1 trial of CTX310, a CRISPR-Cas9 editor aimed at hepatic ANGPTL3. NEJM, 2025.
Checked 2026-11-20
Paper
SELECTWeekly semaglutide reduced major cardiovascular events versus placebo in people with cardiovascular disease and overweight or obesity, without diabetes. Hazard ratio 0.80.
Checked 2026-11-20
Paper
VESALIUS-CVEvolocumab in people without a prior myocardial infarction or stroke. The primary 3-point MACE hazard ratio was 0.75.
Checked 2026-11-20
Paper
Lp(a)HORIZONPelacarsen lowered lipoprotein(a) and did not reduce major cardiovascular events. Hazard ratio 1.02.
Checked 2026-11-20
Paper
ZEUSZiltivekimab lowered interleukin-6 and did not reduce cardiovascular events versus placebo. Hazard ratio 0.99.
Checked 2026-11-20
Government
WHO Global Health EstimatesDownloadable death counts by cause, age, and sex for 2000 through 2023, from Global Health Estimates 2023.
Checked 2026-11-20
The burden behind it
Ischaemic heart diseaseWHO #1 in 2023
LDL-driven plaque narrows the coronary arteries over decades. A plaque ruptures, a clot forms, and heart muscle downstream dies. Blood pressure, cholesterol, smoking, diabetes and age drive it.
Counted only under heart disease. Hypertension keeps stroke, and longevity keeps stroke and dementia. These 9,469,357 deaths are not added to either of those problems.
9.5M15.5% of all deaths
Deaths in the causes this problem addresses, from WHO 2021 and GBD 2023. Not deaths this problem would prevent. A cause shared by two problems is counted under both, so sums across problems overlap.
Why it is not solved yet
Biggest blocker
Ischaemic heart disease deaths are still rising even though some approved drugs already reduce cardiovascular events in trials.
- WorkRead SELECT and VESALIUS-CV next to Lp(a)HORIZON and ZEUS before treating a biomarker change as fewer deaths.
- FundFund a program that measures whether people at high risk actually receive a drug that already reduced events in a trial.
- RunIf you run a clinic, count how many eligible patients are on a therapy with a positive cardiovascular outcome trial.
Why, and how we know
WHO counts 6,429,003 deaths in 2000 and 9,469,357 in 2023. SELECT and VESALIUS-CV reduced events. Inference: the binding constraint is not the absence of a first effective drug. How much of the rise is untreated risk, ageing, or a mechanism those drugs do not touch was not separated in this pass.
Wrong if: A later WHO edition shows ischaemic heart disease deaths back at the 2000 count, or the event reductions in SELECT and VESALIUS-CV fail to replicate.
Found: Lp(a)HORIZON and ZEUS, both published in 2026, did not reduce cardiovascular events (hazard ratios 1.02 and 0.99). Lowering lipoprotein(a) and interleukin-6, in those two trials, was not enough.
On it: SELECT investigators, VESALIUS-CV investigators, Lp(a)HORIZON investigators, ZEUS investigators
WHO Global Health Estimates 2023, global deaths workbook (checked 2026-11-20) · SELECT trial of semaglutide, NEJM · VESALIUS-CV trial of evolocumab, NEJM · Lp(a)HORIZON trial of pelacarsen, NEJM · ZEUS trial of ziltivekimab, NEJM
Companies working on this
0 sourced companies. Links are the company page or the source already on file.
No sourced company is on file.
Industry sponsors on active trials
183 distinct industry sponsors. Each link is the query for that sponsor. Top names by trial count.
- Genoss Co., Ltd. · 13 trials
- Novartis Pharmaceuticals · 9 trials
- Abbott Medical Devices · 7 trials
- CoreAalst BV · 7 trials
- HeartFlow, Inc. · 6 trials
- Abiomed Inc. · 5 trials
- Amgen · 5 trials
- Biosensors Europe SA · 5 trials
Company affiliations on recent papers
OpenAlex stops at 200 institutions for this query, so the count is not in the score. These are the top names from that capped list.
- Brigham and Women's Hospital · 11 works
- Amgen (United States) · 10 works
- University of Toronto · 9 works
- Karger Publishers (Switzerland) · 9 works
- University of Turin · 9 works
- Universidade de São Paulo · 8 works
- Thrombolysis in Myocardial Infarction Study Group · 8 works
- St. Michael's Hospital · 7 works
Supply and demand
This score does not change the priority rank. Demand 56. Supply 37. Gap 19.
- Related deaths / yr: 9,469,357 deaths/yr Source
- Burden feed: not yet sourced
- OpenAlex works, last 12 months: 5,785 works Source
- NIH RePORTER funding: 316,484,990 USD Source
- OpenAlex company affiliations: count capped Source
- ClinicalTrials.gov active trials: 2,265 active trials Source
- ClinicalTrials.gov industry sponsors: 183 industry sponsors Source
- Federal Register documents: not yet sourced
- USAspending awards: 125 awards Source
- SEC EDGAR Form D filings: not yet sourced
- openFDA current drug shortages: not yet sourced
- Wikipedia pageviews (attention, not demand): 692,372 pageviews Source
- Sourced companies on file: 0 companies
- Sourced founders: 0 founders
- Sourced funders: 0 funders
- Annual capital: not yet sourced
Who is moving on Heart disease
A human checks every entry. Nothing here can be bought.
Open starts
0 willing to start
0 so far. Be first.
Open joins
0 want in
No companies tracked yet.
Open capital
0 allocators watching
0 so far. You can stay anonymous.
Act on Heart disease
Cite this
Year mismatch: Deaths are WHO Global Health Estimates for 2023. Prevalence is GBD 2021, as reported in 2025.
- optimism.fun. (2026). Heart disease. https://optimism.fun/p/heart-disease
- NCHS Vital Statistics Rapid Release No. 44 (July 2026): heart disease was the leading cause of death in 2025, with 694,708 deaths. Provisional data as of 10 May 2026. This is all heart disease, not the global ischaemic heart disease count. (2026). US heart disease deaths, 2025, provisional: 694,708. https://www.cdc.gov/nchs/data/vsrr/vsrr044.pdf
- WHO Global Health Estimates 2023, global deaths workbook. https://cdn.who.int/media/docs/default-source/gho-documents/global-health-estimates/deaths_global_2026-09-30.xlsx
- WHO, The top 10 causes of death (2 October 2026). https://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death
- Liang et al., global burden of ischaemic heart disease, GBD 2021. https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2025.1569179/full
- SELECT and VESALIUS-CV, New England Journal of Medicine (2026). Tractability. https://www.nejm.org/doi/full/10.1056/nejmoa2307563
- Liang et al., Frontiers in Public Health, 2025: 254,276,268 prevalent cases in 2021, from GBD 2021 (2021). people living with ischaemic heart disease: 254,276,268. https://doi.org/10.3389/fpubh.2025.1569179 https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2025.1569179/full